DelveInsight’s Rheumatoid Arthritis Market Insights Report offers a detailed analysis of Disease, its causes, symptoms, diagnostics modalities and treatment options. 

The report also offers comprehensive insights into Rheumatoid Arthritis market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing Rheumatoid Arthritis clinical trials, collaboration in the space, and key pharmaceutical companies actively pushing the growth of Rheumatoid Arthritis market size forward in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan). 

 

Some of the key highlights from the Rheumatoid Arthritis Market Insights: 

• The total Rheumatoid Arthritis prevalent cases  were found to be 4,356,793 cases in 2017 in the 7MM, which are anticipated to increase during the study period, i.e., 2017–30. 
• The United States, in 2017, accounted for the highest number of cases in the 7MM.
• AbbVie’s JAK inhibitor Rinvoq (upadacitinib) is one of the major contenders among this drug class for RA. This candidate has shown strong efficacy, including the superiority of Humira. However, Rinvoq approved with a label warning serious infections, malignancy, and thrombosis like older JAK inhibitors Xeljanz (tofacitinib) and Olumiant (baricitnib). 
• Some of the Key Companies are: GlaxoSmithKline, R Pharm, Gilead and Galapagos NV, Taisho Pharmaceuticals, Ablynx, Viela Bio, Aclaris Therapeutics, AbbVie, Bristol Myers Squibb and Many Others
• Gilead and Galapagos NV’s Filgotinib, which is in the registrational stage and is expected to be launched in the 7MM.

 

Learn more by requesting for sample @ Rheumatoid Arthritis Market Landscape 

 

Rheumatoid Arthritis Overview:

Rheumatoid arthritis is a chronic inflammatory or autoimmune disease which is known to affect the joints of the body adversely. An autoimmune disorder is a condition where the immunity system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harm the joints. Even after years of research, the cause of rheumatoid arthritis is still unknown. 

Rheumatoid Arthritis is found to be more common in women than men.

 

Rheumatoid Arthritis Symptoms:

Symptoms include joint pain, stiffness, swelling, and decreased movement of the joints. 

 

Rheumatoid Arthritis Diagnosis:

Diagnosis is made by a combination of patient’s symptoms, assessment of risk factors, results of doctor’s examination, family history, a joint assessment by ultrasound sonography, & assessment of laboratory markers.

 

For more insights into Disease, causes and treatment, reach out @ Rheumatoid Arthritis Treatment Landscape. 

 

Rheumatoid Arthritis Epidemiology Segmentation 

The Rheumatoid Arthritis Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

• Rheumatoid Arthritis Prevalence 
• Severity Specific Rheumatoid Arthritis Prevalence 
• Diagnosed and Treatable Cases of Rheumatoid Arthritis

 

Rheumatoid Arthritis Pipeline Therapies and Key Companies 

•  Otilimab/GSK3196165 (GlaxoSmithKline)
•  Olokizumab (R Pharm)
•  Filgotinib (Gilead and Galapagos NV)
•  Ozoralizumab/TS-152 (Taisho Pharmaceuticals/Ablynx)
•  VIB4920 (Viela Bio)
•  ATI-450/CDD-450 (Aclaris Therapeutics)
•  ABBV-3373 and ABBV-154 (AbbVie)
•  Branebrutinib (Bristol Myers Squibb)
•  JTE-051 (Akros Pharma/Japan Tobacco)
•  MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
•  Dekavil/F8IL10 (Pfizer/Philogen)
•  PF-06651600/Ritlecitinib (Pfizer)
•  Evobrutinib/M2951 (Merck)
•  PF-06650833 (Pfizer)
•  Fenebrutinib/GDC-0853/RG7845 (Roche/Genentech)
•  Bimekizumab (UCB Pharma/PRA HEALTH SCIENCES)
•  Namilumab/IZN-101/AMG203 (Izana Bioscience/Takeda)
•  MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
•  ABX464 (Abivax)
• SKI-O-703 (Genosco/Oscotec)
• HB-AdMSCs (Hope Biosciences)

 

Rheumatoid Arthritis Market Drivers:

• Increase in the prevalence population of RA
• Increase in the geriatric population
• Rich Emerging Pipeline
• And Many Others

 

Scope of the Report

• 11 Years Forecast
• 7MM Coverage 
• Descriptive overview of Rheumatoid Arthritis, covering causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight into Rheumatoid Arthritis epidemiology and treatment in the 7MM
• Current and emerging therapies for Rheumatoid Arthritis
• Rheumatoid Arthritis market drivers and barriers 

 

Table of Contents 

1	Key Insights
2	Report Introduction
3	Competitive Intelligence Analysis for Rheumatoid Arthritis
4	Rheumatoid Arthritis Market Overview at a Glance
5	Executive Summary of Rheumatoid Arthritis
6	Rheumatoid Arthritis Epidemiology and Market Methodology
7	Rheumatoid Arthritis Epidemiology and Patient Population
8	Rheumatoid Arthritis Patient Journey
9	Treatment Algorithm, Current Treatment, and Medical Practices
10	Key Endpoints in Rheumatoid Arthritis Clinical Trials
11	Rheumatoid Arthritis Marketed Therapies
12	Rheumatoid Arthritis Emerging Therapies
13	Rheumatoid Arthritis: 7 Major Market Analysis
14	Attribute analysis
15	Access and Reimbursement Overview of Rheumatoid Arthritis
16	KOL Reviews
17	Case Reports
18	Rheumatoid Arthritis Market Drivers
19	Rheumatoid Arthritis Market Barriers
20	SWOT Analysis
21	Disclaimer
21	DelveInsight Capabilities
22	About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Market Research, and Business Consultant focused purely on life sciences. It assists pharma companies by providing them with end-to-end solutions to boost their performance.

Get access to all the Pharma and healthcare market research reports through our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market